Reaction
Pneumonia Streptococcal reporting signals
As of the last recalculation, Pneumonia Streptococcal appears in 1,084 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is CANAKINUMAB (PRR 51.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Canakinumab | 28 | 51.0 | 51.1 |
| Methocarbamol Tablets | 27 | 31.7 | 31.8 |
| Nicotine Polacrilex Mini | 22 | 28.7 | 28.8 |
| Nicotine Polarilex | 22 | 28.7 | 28.8 |
| Erythromycin | 24 | 25.1 | 25.1 |
| Methocarbamol | 27 | 23.4 | 23.4 |
| Ganciclovir | 12 | 22.8 | 22.8 |
| Tiotropium Bromide Inhalation Spray | 13 | 22.5 | 22.6 |
| Ganciclovir Sodium | 12 | 22.0 | 22.0 |
| Sirolimus | 15 | 21.7 | 21.7 |
| Ciclesonide | 14 | 20.0 | 20.0 |
| Colchicine | 26 | 19.4 | 19.4 |
| Zinc | 22 | 17.5 | 17.5 |
| Zinc Chloride | 22 | 17.3 | 17.4 |
| Zinc Gluconate | 22 | 16.5 | 16.5 |
| Mesna Injection | 7 | 16.4 | 16.4 |
| Mesna | 7 | 16.1 | 16.1 |
| Nevirapine | 7 | 15.0 | 15.0 |
| Ceftriaxone Sodium | 28 | 14.4 | 14.4 |
| Efavirenz | 8 | 13.9 | 13.9 |
| Melphalan | 16 | 13.7 | 13.7 |
| Melphalan Hydrochloride | 17 | 13.2 | 13.2 |
| Oseltamivir | 5 | 12.1 | 12.1 |
| Ceftriaxone | 20 | 11.9 | 11.9 |
| Nicotine Polacrilex | 23 | 11.8 | 11.8 |
| Mesalamine | 33 | 11.6 | 11.6 |
| Remdesivir | 8 | 11.6 | 11.6 |
| Oseltamivir Phosphate | 14 | 11.1 | 11.1 |
| Nicotine | 23 | 11.1 | 11.1 |
| Mepolizumab | 26 | 10.3 | 10.3 |
| Fludarabine Phosphate | 20 | 9.9 | 9.9 |
| Naltrexone | 13 | 8.2 | 8.2 |
| Carfilzomib | 10 | 6.8 | 6.8 |
| Ravulizumab | 4 | 5.7 | 5.7 |
| Pomalidomide | 23 | 4.4 | 4.4 |